Skip to main content

Regencell Bioscience Holdings Ltd (RGC) Stock

Regencell Bioscience Holdings Ltd Stock Details, Movements and Public Alerts

Stock Details

Regencell Bioscience Holdings Ltd (RGC), a prominent company in the healthcare sector within the drug manufacturers - specialty & generic industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $23.23. Over the past 52 weeks, it has ranged between $0.33 and $83.60. This places the current price at 27.8% of its 52-week high and 6855.1% above its 52-week low. Recent trading volume was recorded at 89,094. The 14-day Relative Strength Index (RSI) stands at 45.92, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $28.29 by 17.89%. Similarly, it is above its 200-day moving average of $19.18 by 21.12%. The MACD histogram is -0.50, indicating bearish momentum (MACD Line: -0.30, Signal Line: 0.19).

52-Week Range

$83.60 - $0.33

-72.21% from high · +6855.09% from low

Avg Daily Volume

144,784

20-day average

100-day avg: 356,902

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

2363.44

EV/EBITDA

-44.58

EPS (TTM)

-$0.01

Beta

2.07

More volatile than market

Q:How is RGC valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is RGC's risk profile compared to the market?
With a beta of 2.07, Regencell Bioscience Holdings Ltd is significantly more volatile than the market. For every 10% market move, this stock tends to move 21% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 2363.44 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-3,692,293

Return on Equity

-54.80%

Return on Assets

-33.20%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is RGC's business model?
Profitability metrics are not available for this stock.
Q:What are RGC's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$11.5B

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

494.49M

Book Value/Share

$0.01

Asset Type

Common Stock

Q:What is RGC's market capitalization and position?
Regencell Bioscience Holdings Ltd has a market capitalization of $11.5B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 494.49M shares outstanding, the company's ownership is relatively concentrated. As a participant in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry, it competes with other firms in this sector.
Q:How does RGC's price compare to its book value?
Regencell Bioscience Holdings Ltd's book value per share is $0.01, while the current stock price is $23.23, resulting in a price-to-book (P/B) ratio of 2323.00. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Fundamentals last updated: Mar 15, 2026, 02:21 AM

Technical Indicators

RSI (14-day)

45.92

Neutral

50-Day Moving Average

$28.29

-17.89% below MA-50

200-Day Moving Average

$19.18

21.12% above MA-200

MACD Line

-0.30

MACD Signal

0.19

MACD Histogram

-0.50

Bearish

Q:What does RGC's RSI value tell investors?
The RSI (Relative Strength Index) for RGC is currently 45.92, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret RGC's MACD and moving average crossovers?
MACD analysis shows the MACD line at -0.30 below the signal line at 0.19, with histogram at -0.50. This bearish crossover indicates downward pressure. The 50-day MA ($28.29) is above the 200-day MA ($19.18), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 1, 2026, 12:30 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for RGC and get notified when the price changes.

Stay Ahead of the Market with Regencell Bioscience Holdings Ltd Alerts

Set up price alerts for Regencell Bioscience Holdings Ltd and get notified instantly when the price hits your target. Never miss an important price movement again.